Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from
Fate Therapeutics lost less money than people expected this quarter, and made more sales than predicted. When a company doing research loses less money and grows sales, it can mean their work is moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.